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Effective anti-adhesives of uropathogenic Escherichia coli
Urinary tract infections (UTIs) caused by uropathogenic 
Escherichia coli (UPEC) are among the most common infec-
tious diseases in humans. Due to their frequent occurrence 
in the community and nosocomial settings, as well as the 
development of resistance to the commonly prescribed anti-
microbial agents, an enormous financial burden is placed 
on healthcare systems around the world. Therefore, novel 
approaches to the prevention and treatment of UTIs are 
needed. Although UPEC may harbour a plethora of viru-
lence factors, type I fimbriae and P pili are two of the most 
studied adhesive organelles, since the attachment to host 
cells in the urinary tract is a crucial step towards infection. 
Design of receptor analogues that competitively bind to 
UPEC surface adhesins placed at the top of pili organelles 
led to the development of anti-adhesive drugs that are in-
creasingly recognized as important and promising alterna-
tives to antibiotic treatment of UTIs.
Keywords: urinary tract infections, type I fimbriae, P pili, 
mannosides, cranberry, polyphenols
Urinary tract infections (UTIs), including both cystitis and pyelonephritis, are among 
the most common bacterial infections particularly affecting females (1). These infections 
often recur within the months after primary infection, even after treatment with appropri-
ate antibiotics. Nearly one-third of women will have an acute UTI by the age of 24 and 
about 25 % of these individuals will experience at least one recurrent UTI within six 
months of the initial infection (1). The paramount pathogen associated with UTIs is uro-
pathogenic Escherichia coli (UPEC). UPEC strains are responsible for more than 80 % of 
UTIs in both sexes. They are difficult to treat because of increasing antimicrobial resistance 
to standard therapy (2) and high recurrence rates (3), and therefore represent a serious 
health problem. Resistance of UPEC to the commonly prescribed antibiotics has risen in 
the past decade, leading to increased treatment costs and antibiotic multiresistance (4, 5). 
Therefore, novel approaches to the prevention and treatment of UTIs are needed, which 
would have a strong impact on patient health care and medical expenses. UPEC can 
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(in both extracellular and intracellular niches) and urine. It is believed that Escherichia coli 
(E. coli) gets introduced into the urethra from the intestine. More precisely, E. coli strains 
travel from gut to the vaginal and periurethral area and colonize the bladder, causing the 
most common form of UTIs –- cystitis. UTI can then proceed from bladder via ureters to the 
kidney and cause pyelonephritis. Pyelonephritis is a less common type of symptomatic 
UTIs than cystitis (6). UPEC can cause acute, chronic, persistent and recurrent infections 
(7, 8). In chronic and complicated UTIs, the strains of E. coli are often mixed (9).
E. coli includes highly versatile bacteria. Commensal E. coli is harmless and is actu-
ally an important part of human intestinal flora (10). Some strains of E. coli may cause in-
fections with the help of their virulence factors. This trait can be used to group them, and 
so UPEC strains can be found within the extraintestinal pathogenic E. coli (ExPEC) group. 
ExPEC exists in the gut, but can disseminate and colonize other host niches (including 
urinary tract), resulting in disease. ExPEC pathotype is known to express a number of 
virulence factors used for successful colonization of host cells. Main adherence factors are 
supramolecular, filamentous, adhesive organelles called pili or fimbriae that extend from 
the bacterial surface. Common adhesive organelles in UPEC are fimbriae type I, P, S and 
F1C pili, encoded by the fin, pap, sfa and foc operons, resp. (10). Type I fimbriae and P pili 
are two of the most studied adhesive organelles because they are encoded by many UPEC 
strains. Lectins found on adhesive organelles contain high portions of hydrophobic amino 
acid residues and therefore represent common features of bacterial cell surface hydropho-
bicity, which is conducive to adhesion to host cells (11). UPEC tends to colonize the bladder 
mucous membrane in microbacterial communities known as biofilm. These UPEC micro-
colonies favor long-term persistence in host tissue, leading to the evolution of multidrug-
resistant strains (12).
Stages of pathogenesis leading to the development of UTIs include bacterial adher-
ence to host tissues, colonization within the host, avoidance of host defense mechanism 
and damage of host tissues (13). Since the ability of UPEC to bind to host tissues enables 
efficient colonization of the urinary tract and allows bacteria to withstand the bulk flow of 
urine (thus promoting UPEC invasion), it can be concluded that successful attachment of 
UPEC is a crucial step in the development of UTIs. UPEC preferentially colonizes the blad-
der causing cystitis, but can also ascend through the ureters into the kidneys causing py-
elonephritis. Type I fimbriae play a pivotal role in bacterial adhesion. They are major fa-
cilitators of UPEC entry into host cells, and prevalent adhesins expressed by most of the 
pathogenic strains. P pili are the second common virulence factor of UPEC, which is pre-
dominantly associated with pyelonephritis (14). For example, UPEC mutants that lack the 
main adhesive protein from type I pili organelles are unable to effectively invade bladder 
epithelial cells either in cell culture model systems or in mice (15, 16).
TYPE I FIMBRIAE
Type I pili organelles (also known as type I fimbriae) are uniformly distributed on 
bacteria surface in at least 90 % of all known UPEC strains and are one of the most abun-
dant surface structures (7, 8). They mediate complementary attachment to specific mole-
cules on the host epithelium containing mannose (17). They are rod-like with a width of 
approximately 7 nm and length between 0.1 and 2 mm. These organelles are composite 
protein structures consisting of a thick right-handed helical rod made up of repeating 
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immunoglobulin-like FimA subunits (500–3000 FimA subunits) joined to a thick distal tip 
fibrillum containing two adaptor proteins, FimG and FimF, and the adhesin protein called 
FimH located at the top of the pili (Fig. 1a). FimH adhesin specifically recognizes terminal 
mannose (Fig. 1b) of mannosylated receptors on the surface of mammalian bladder epi-
thelial cells (18–20). An integral membrane glycoprotein present on bladder surface, called 
uroplakin 1a, is the main natural receptor for FimH (21). This process facilitates the colo-
nization and development of UTI (16, 21–23). FimH is essential for the invasion and abil-
ity of bacteria to colonize the bladder in chronic infections (7, 8). It has been confirmed that 
FimH has a critical role in human UTI (24, 25) and therefore therapeutic agents specifically 
targeting FimH have been developed.
FimH adhesin is a protein with 279 amino acid residues and is folded into two do-
mains: a lectin receptor-binding and a pilin domain, which are connected by a short ex-
tended linker (26). The N-terminal domain is a mannose-binding domain comprising 156 
amino acid residues while the C-terminal domain is a pilin domain. Pilin domain includes 
from 160 to 279 amino acid residues. This domain is responsible for the anchoring of the 
adhesin to the pilus. The first crystal structure of FimH was determined in 1999 (26). FimH 
was in a complex with its chaperone, FimC. FimH was complexed with the FimC chaper-
one in order to stabilize the assembly because FimH cannot be crystallized in pure form. 
Cyclohexylbutanoyl-N-hydroxyethyl-d-glucamide (C-HEGA) was also added for crystal-
lization. It was found that C-HEGA binds to the carbohydrate-binding domain (CRD) of 
FimH, located at the top of the type I pili and that the glucamide moiety of C-HEGA adopts 
a conformation closely resembling a mannose pyranoside ring of α-anomeric configura-
tion (26). Crystal structure of the chaperone:adhesin (FimC:FimH) complex with α-d-
mannose bound to the carbohydrate-binding site was published in 2002 (27). This crystal 
structure revealed which amino acid residues in CRD domain were important for man-
nose binding. The mannose-binding pocket of FimH is composed of amino acid residues, 
which are invariant in all strains of E. coli. Mutations in these residues disrupt mannose 
binding (25).
Mannose binds in a negatively charged pocket and makes ten direct H-bonds with 
residues in the CRD domain. All hydroxyl groups of the mannose sugar ring (Fig. 1b) 
interact with Phe1, Asn46, Asp47, Asp54, Gln133, Asn135, Asp140 and Phe142 residues. 
Fig. 1. Representation of: a) type I pili, b) structure of mannose in its α-anomeric configuration, and 
c) mannose binding pocket of FimH (27).
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The mannose-binding pocket is surrounded by hydrophobic residues: Ile13, Tyr48, Ile52, 
Tyr137 and Phe142 (Fig. 1c). The side chains of Tyr48 and Tyr137 are positioned so as to 
form a “tyrosine gate” (27).
Further, another crystallographic study was published in 2005 (28). In that study, two 
FimH proteins from different bacterial strains were used, both truncated only to the FimH 
lectin domain. FimH complexes with the mannose derivative butyl α-d-mannoside were 
formed. The structure of FimH:butyl α-d-mannoside complex shows that the lipophilic 
butyl moiety of the mannoside extended out of the mannose binding pocket toward the 
“tyrosine gate” and that van der Waals interactions with Tyr48 and Tyr137 from the “gate” 
were formed. This example confirmed that the “tyrosine gate” is very important for effi-
cient binding of lipophilic FimH antagonists, especially aromatic ones (mannose ligands 
with aromatic aglycon moiety). In addition, it can be concluded that revealing the de-
tailed structure of the FimH CRD domain can lead to rational design of efficient anti-
adhesives for type I fimbriated UPEC.
P PILI
P pili (P fimbriae) are responsible for mannose resistant adhesion, since they adhere 
to the receptors containing the digalactoside unit (α-d-galactopyranosyl-(1-4)-β-d-
galactopyranoside) moiety shown in Fig. 2a (29). This bacterial structure is composed of 
several proteins: PapA, PapK, PapE, PapF and PapG. Adhesion subunit is PapG and it is 
placed at the top of the P pili, similarly as the FimH is placed at the top of the type I pili 
(Fig. 2b). The galabiose-binding site is located at the PapG unit (29). Gal-Gal moiety as the 
receptor for P fimbriae is found abundantly on the surface of epithelial cells lining the 
urinary tract. The association of P pili with pyelonephritis could be due to a large amount 
of galactose receptors present in renal glycolipids (30). Binding of P pili to the Gal-Gal 
moiety on uroepithelial cells induces release of sphingolipid ceramides, agonists of TLR4, 
which activate the immune cell response. This crosstalk favors production of proinflam-
Fig. 2. Structure of: a) α-d-galactopyranosyl-(1-4)-β-d-galactopyranoside, b) P pilus, and c) globoside.
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matory cytokines, chemokines and recruitment of neutrophils, which means that P fim-
briae are implicated in triggering inflammation processes. This initial response is benefi-
cial in initiating bacterial clearance, but it will also cause damage to the surrounding tissue 
and is associated with renal complications. This finding can explain the association of P-
fimbriated E. coli with acute pyelonephritis (31).
Three distinct PapG adhesions have been identified: PapGI, II and III (32). Each of 
them recognizes a specific receptor with a characteristic galabiose core structure. PapGII 
is predominantly associated with human pyelonephritis and specifically binds to globote-
traosylceramide, globoside (GbO4). Globoside (Fig. 2c) is a glycolipid that consists of a di-
galactoside core structure attached to N-acetyl-galactosamine on one side, and is linked by 
glucose to a ceramide group on the other side. Crystal structure of the PapGII binding 
domain with bound GbO4 elucidated the molecular basis of key interactions for the adhe-
sion process. Structure of the PapGII receptor-binding domain can be divided into two 
regions. Region 1 includes C-terminus, while region 2 contains the binding site and N-
terminus. Three-dimensional structure of the adhesin-ligand complex revealed a network 
of interactions leading to kidney colonization. The receptor binding site of PapGII is lo-
cated in a pocket formed by strands j, g, k and α-helix. The ligand, tetra-saccharide GbO4, 
made of residues A (to N-acetyl-galactosamine), B, C (both galactose) and D (glucose), 
binds in the binding pocket in V-shape. Hydrophobic, aromatic interactions between 
Trp107 and the non-polar part of the digalactoside core and polar contact between Trp107 
and hydroxyl group of glucose are crucial for receptor binding (32). Other contacts impor-
tant for the stabilization of the receptor-ligand complex are additional electrostatic interac-
tions with the corresponding Lys and Arg residues and H-bonding with hydroxyl groups 
of tetra-saccharide GbO4. These molecular details of host-pathogen interactions provide a 
framework for the development of novel antimicrobial agents.
S AND F1C PILI
S pili and F1C pili (also known as S and F1C fimbriae) are implicated in the develop-
ment of UTIs as well, since they can both bind to epithelial and endothelial cells of the 
kidney and lower human urinary tract (33). S fimbrial adhesins I and II (usually abbrevi-
ated SfaI and II) are readily produced by UPEC, but also by ExPEC, which may cause 
newborn meningitis and sepsis (34). Recognition points for S fimbrial adhesion are a-sialyl-
2,3-β-lactose-containing receptors found on the host epithelial cells and extracellular ma-
trix (34, 35). The adhesin complex of S pili consists of four proteins in the sfa gene cluster: 
the major subunit protein SfaI-A, and three minor subunit proteins SfaI-G, SfaI-H and 
SfaI-S (36). The latter protein (i.e., SfaI-S) is located at fimbrial tips and is primarily respon-
sible for mediating the sialic acid-specific binding activity of S pili (36). Also, it must be 
noted that the gene sfaI-S is the only minor protein gene with the propensity to increase 
the degree of fimbriation and provide adhesion properties for a non-adhesive derivative 
E. coli K-12 strain that lacks the sfaI-A major subunit gene, but also sfaI-G and sfaI-H genes 
(36). A pathogenicity island containing all these S-fimbria-encoding operons has been ac-
quired by horizontal gene transfer (34).
Akin to already described P and S pili, F1C pili (or F1C fimbriae) are evolutionarily 
selected to withstand the conditions encountered in the upper urinary tract (37). These pili 
have the affinity for globotriaosylceramide found in the kidney epithelium, but also for 
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galactosylceramide present in the kidney, ureters and the urinary bladder (38). It has been 
shown that F1C-fimbrial adhesins bind to structures containing the GalNAcβ1-4Galβ 
sequence of glycolipids, which are preferentially expressed by isolates causing UTIs (34). 
An additional binding to Galβ1-4Glc and GlcNAcβ1-3Galβ (which are considered as low-
affinity functional receptor sites) is also observed (39). The minutest carbohydrate moiety 
of glycolipids required for the binding of F1C pili is the β1-linked galactose or glucose, 
assuming they are found in proper configuration and conformation (39). Constituents of 
the F1C fimbrial complex are the major subunit protein FocA, followed by FocC crucial for 
pili formation, as well as minor subunits known as FocF, FocG and FocH (40, 41), showing 
a high sequence homology to both major and minor subunits of S pili (39). Moreover, the 
biomechanical properties of F1C pili have been deemed quite important for the ability of 
E. coli to endure shear forces resulting from rinsing urine flows (37).
MANNOSIDES AS EFFICIENT ANTI-ADHESIVES OF TYPE I FIMBRIATED UPEC
The concept of anti-adhesion therapy as an alternative to standard antibiotic therapy 
of UTIs means that multi-antibiotic resistance could be suppressed simply by using ade-
quate anti-adhesion drugs (31). It has been known since the 1970s that adhesion of UPEC 
can be inhibited by mannose and methyl α-d-mannopyranoside (MeMan), which is nowa-
days usually used as a reference compound in assays. In the meantime, a large number of 
glycomimetics, derivatives of α-d-mannose (α-d-mannopyranosides), were reported as 
high-affinity ligands for FimH adhesin. Some research has been focused on multivalent 
glycomimetics such as oligosaccharides, glycoclusters and glycodendrimers that have 
two or more mannose subunits attached. Many of these compounds had been prepared 
and tested before the three-dimensional structure of the FimH CDR domain was known. 
Multivalent approach was based on the multivalency effect that was observed in other 
carbohydrate-lectin interactions where multiple carbohydrate-lectin contacts occur lead-
ing to increased strength of the overall interaction. This was a promising approach, 
which provided several very potent inhibitors of UPEC adhesion. Structures of the se-
lected potent glycomimetics with different architecture are shown in Fig. 3. All of them 
have high relative inhibitory potency (RIP) determined with respect to MeMan as refer-
ence compound (inhibitory potency of MeMan is 1). RIP values do not depend on the 
assay system. Glycocluster 1 with branched amine as a non-carbohydrate core and three 
attached mannose subunits have a RIP value of 106, while its analogues with two and 
four mannose subunits show lower RIP (42). Trivalent mannose cluster 2 (43) with a 
chemically different spacer, an ethylene glycol spacer, showed even 10-times better in-
hibitory activity than glycocluster 1. Another impressive result was obtained by the 
carbohydrate-centered dendrimer 3, which exhibited more than 11 thousand better ac-
tivity compared to MeMan (44). Excellent anti-adhesive activity was exhibited by tetra-
valent mannoside 4 containing alkyne moieties (45). A large number of potent UPEC 
inhibitors were prepared using “click” chemical reactions characterized by specific and 
fast chemical transformations, such as triazole mannosides synthesized by copper-cat-
alyzed azide-alkyne cycloaddition (46). Lysine-based dendrimer 5 has a monosaccharide 
as the branching element and is structurally similar to oligosaccharides (47). Its RIP is 
approximately the same as the one of compound 1. Carbohydrate-centered cluster 6 (48) 
showed approximately two-fold improvement of activity compared to dendrimer 5. All 
of these multicarbohydrate compounds bind to FimH with great avidity, but the ob-
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Fig. 3. Structures of potent multivalent anti-adhesives: tris[(α-d-mannopyranosylthiourylene)ethyl]
amine (1), tris-[2’’’-({2’’-[2’-(α-d-mannopyranosyloxy)ethoxy]ethyl}carbamoyl)ethyl]nitromethane (2), 
methyl 3,6-di-O-(6-{3,6-di-O-[6-(α-d-mannopyranosyloxy)-4-thiahexyl]-α-d-mannopyranosyloxy}-4-
thiahexyl)-α-d-mannopyranoside (3), tetrakis[({3-[4-(α-d-mannopyranosyloxy)phenyl]prop-2-yn-1- yl}
oxy)methyl]methane (4), mannosylated L-lysine-based hexadecamer (5), [3-O-(α-d-manno py ra-
nosyloxy)propyl] 2,3,4,-tri-O-[3-(α-d-mannopyranosyloxy)propyl]-6-{2,3,4,6-tetra-O-[3-(α-
d-mannopyranosyloxy)propyl]-α-d-galactopyranosyloxy}-α-d-glucopyranoside (6).
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served multivalency effects are still not fully understood. One of the explanations of the 
multivalency effect is based on statistically favored rebinding of a mannose ligand, 
meaning that a larger number of mannose residues present in the proximity of CRD will 
increase the probability of a binding event to occur. These multivalent adhesion inhibi-
tors are high-molecular-mass structures and are not suitable for clinical development as 
oral drugs because of high polarity, which leads to poor absorption from the gastroin-
testinal tract.
Fig. 4. Efficient FimH antagonists: butyl α-d-mannopyranoside (7), heptyl α-d-mannopyranoside (8), 
N-(adamantan-1-yl)-3-α-d-mannopyranosyloxy-2-methylpropanamide (9), (R)-N-ferrocenylbutyl-3-α-
d-mannopyranosyloxy-2-methylpropanamide (10), p-nitrophenyl α-d-mannopyranoside (11), p-nitro-
o-chlorophenyl α-d-mannopyranoside (12), 5-methylumbelliferyl α-d-mannopyranoside (13), o-chlo-
ro-p-[N-2-ethoxy-3,4-dioxocyclobut-1-enyl)amino]phenyl α-d-mannopyranoside (14), methyl 
3-[4-(α-d-mannopyranosyloxy)phenyl]benzoate (15), 3’-chloro-4’-(α-d-mannopyranosyloxy)-
biphenyl-4-carbonitrile (16).
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Another approach in research and development of efficient anti-adhesives of type 
I fimbriated UPEC is focused on compounds with only one mannose subunit attached 
to the non-carbohydrate part (aglycon). Based on the X-ray structures of FimH:mannoside 
(27, 49, 50) complexes, which reveal key molecular interactions for FimH binding on man-
nosylated structures, it was concluded that introduction of a non-carbohydrate hydro-
phobic (or lipophilic) moiety on a single α-mannosyl residue positively affects the in-
hibitory activity. Non-carbohydrate parts could enable hydrophobic interactions with 
lipophilic side-chains present in CRD. A large number of mannosides with hydrophobic 
aglycons such as acyclic, cyclic and/or aromatic (monoaromatic and extended aromatics 
such as biphenyls) moieties attached to α-d-mannose were synthesized and biologically 
evaluated. Aglycon moieties were altered regarding the core structures, positions and 
types of substituents, and the length of linkers between α-d-mannose and aglycon. Se-
lected alkyl, cyclic and aromatic mannosides with excellent anti-adhesion properties are 
shown in Fig. 4. The previously mentioned butyl α-d-mannoside 7 is an example of alkyl 
mannosides that bind to FimH adhesin, leading to the stable FimH:butyl α-d-mannoside 
complex whose crystal structure was determined. Long chain mannoside 8, heptyl α-d-
mannoside, is a stronger inhibitor of the FimH mediated adhesion than its butyl analogue 7 
(28). Attachment of cyclic aglycon with expressed lipophilic character at mannose, like ada-
mantane subunit with 15 carbon atoms in compound 9, also enhances the inhibitory 
activity but only three times (51). Even more potent inhibitors of adhesion (when com-
pared to aliphatic ones) are FimH antagonists with an aromatic aglycon such as ferro-
cene 10 (52, 53), p-nitrophenyl-α-d-mannoside 11 (54), p-nitro-o-chlorophenyl α-d-
mannoside 12 (55), 5-methyl-umbelliferyl-α-d-mannoside 13 (55) and squaric acid 
monoamide mannoside 14 (56). Because of their planar structure and lipophilic charac-
ter, they enable stronger hydrophobic interactions with the CRD domain. Computer 
aided prediction of the chemical structure of potent anti-adhesives based on the known 
3D-structure of FimH is the commonly employed methodology. In essence, this meth-
odology [in combination with structure-activity relationship (SAR) studies] contributed 
significantly to the rapid development of potential therapeutics. Using this approach, it 
was found out that aromatic mannosides must be extended by a second aryl system in 
order to enhance the affinity for FimH. A second aryl system induces Π-Π stacking with 
Tyr48 and Tyr137 from the tyrosine gate, which contributes to stronger binding of in-
hibitors of type I fimbriated UPEC adhesion to FimH adhesin (57, 58). The described 
approach of rational design led to biphenyl FimH inhibitors 15 (49) and 16 (59, 60) with 
nanomolar affinity and excellent potency in an in vivo mouse model. Optimization of 
their pharmacokinetic properties and in vivo efficacy are currently in progress. In gen-
eral, biaryl or ‘two-ring’ mannosides are the largest and most thoroughly tested class of 
FimH antagonists, and they also have the highest potential as novel orally bioavailable ther-
apeutics for UTIs. There are certain predictions that one or more FimH antagonists will 
enter the clinical milieu within the next few years.
POLYPHENOLS AS ANTI-ADHESIVES OF P-FIMBRIATED UPEC
The role of polyphenols found in cranberries in preventing urinary tract infections 
caused by UPEC has been extensively studied by different research groups (61–64). Red 
cranberry is known to contain a plethora of phenolic compounds, most notably flavonols, 
anthocyanins and proanthocyanidins, but also other phytochemicals such as various or-
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ganic acids, terpenes and complex carbohydrates (65). The A- and B-type proanthocyani-
dins are oligomers of flavan-3-ol units, (+)-catechin 17 and (–)-epicatechin 18 units, which 
are bound via C-4 (upper unit)/C-6 or C-8 (lower unit) bonds in both oligomers represented 
by the dimeric flavan-3-ol structures of procyanidin A2 19 and procyanidin B2 20 (Fig. 5). 
Only in A-type proanthocyanidins, an additional ether type bond [C-2 (upper unit)-O-C-7 
(lower unit)] is found (66).
Better understanding of SAR in proanthocyanidins is conceivable today due to tech-
nology advancements – not only in acquiring purified fractions of the compounds that 
enable accurate estimates, but also in confirmation of chemical structure especially em-
ploying high-resolution mass spectrometry (67). It has been shown that only A-type pro-
anthocyanidins are considered to play a key role in the prevention of UTIs caused by E. 
coli (65, 68). Several authors have reported that proanthocyanidins in cranberries have 
uncommon double A-type linkages, which may give them significant structural attributes 
in the anti-adherence action against UPEC (69, 70). Furthermore, the studies that compared 
A-type and B-type proanthocyanidins have shown non-existent or minimal anti-adhesive 
activity of B-type compounds isolated from grape seeds and other sources against UPEC 
in vitro, when compared to proanthocyanidins from cranberries (63).
Rich interactions at the mucosal surface in the gastrointestinal tract may be respon-
sible for the purported health benefits of proanthocyanidins in UTI (67). Recent research 
Fig. 5. Cranberry proanthocyanidin subunits: (+)-catechin (17), (–)-epicatechin (18), epicatechin-
(2β®O®7, 4β®8)-epicatechin (19), epicatechin-(4β®8)-epicatechin (20).
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has demonstrated that higher agglutination of ExPEC and decreased bacterial invasion are 
both correlated with a higher number of A-type bonds and a higher degree of polymeriza-
tion (67). On the other hand, one study has recently reported the appearance of A2-dimers 
in human urine after consumption of cranberry juice (71). Some research teams have also 
detected various phenolic acids and different metabolites in urine of healthy volunteers 
collected after several cranberry products were ingested (65, 71–73).
Indeed, apart from A2 and other A-type proanthocyanidins, de Llano and his coau-
thors (66) described the anti-adhesive activity of other phenolic metabolites with low mo-
lecular mass (namely simple phenols and phenolic acid) against UPEC in vitro, though they 
did not succeed in establishing a consistent structure-activity relationship warranting 
further research. In their work, anti-adhesive activity in a concentration-dependent man-
ner (from 100–500 µmol L–1) was shown for benzoic acid 21, catechol 22, phenylacetic acid 
23, vanillic acid 24 and 3,4-dihydroxyphenyl acetic acid 25 (Fig. 6). As these metabolites are 
generated by the quotidian cranberry metabolism, their synergistic effect with proantho-
cyanidins in UTI prophylaxis may be expected.
Regarding the mechanism underlying these anti-adhesive effects of type A proantho-
cyanidins, Gupta and his colleagues (62) proposed a hypothesis that these compounds 
either modify the structure of P-fimbriae or combine with P-fimbriae of bacteria, since they 
have observed inhibition of adherence of UPEC to P-fimbriae in either sensitive or multi-
drug resistant strains. Polewski et al. (74) used scanning electron microscopy and sug-
gested that cross-linking of surface virulence factors by proanthocyanidins prevents Ex-
PEC invasion. A study by Nicolosi et al. (75) has shown that proanthocyanidins can also 
partially inhibit the activity of E. coli flagella, reducing the overall motility of bacteria. In 
the light of these findings, Amalaradjou and his colleagues (76) demonstrated that trans-
cinnamaldehyde (26), which is a vital component of cinnamon oil, can also substantially 
Fig. 6. Cranberry phenolic metabolites with anti-adhesive activity: benzoic acid (21), catechol (22), 
phenylacetic acid (23), vanillic acid (24), 3,4-dihydroxyphenylacetic acid (25), trans-cinnamaldehyde 
(26).
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inhibit the attachment and invasion of the host tissue cells in the urinary tract by UPEC, 
primarily by decreasing the expression of dominant genes implicated in these processes.
Even though certain studies did not show any benefits of cranberry consumption for 
preventing UTIs (77), the general scientific consensus (based on numerous clinical studies) 
is that cranberry can be considered as an alternative approach to antibiotics in low doses 
for UTI prophylaxis (65, 78), though additional biochemical and clinical research is defi-
nitely necessary. Also, systematic protocols for the synthesis of phenolic conjugates are 
currently under development (79). By using advances in liquid chromatography and mass 
spectrometry, improved quantitative techniques and production of cranberry proantho-
cyanidin standards, parameters such as standardization, authenticity, efficacy and safety 
of cranberry products and dietary supplements may now be precisely measured (80), 
which will definitely help in further research and treatment endeavors.
CONCLUSIONS
UPEC expresses a myriad of virulence factors for a successful colonization of host 
cells. Main adherence factors are adhesive organelles called pili or fimbriae extending 
from the bacterial surface. Common adhesive organelles in UPEC are fimbriae type I, P, S 
and F1C. Type I fimbriae and P pili are two of the most studied adhesive organelles. Design 
of receptor analogues that competitively bind to UPEC surface adhesins FimH and PapG 
placed at the top of pilin type I fimbrae and P pili, respectively, led to the development of 
anti-adhesive drugs that are promising alternatives to antibiotic treatment of UTIs. Com-
pounds that inhibit attachment of UPEC via adhesins FimH and PagG to host cells are 
excellent candidates for the therapeutic use for UTI. X-ray structure-based design strate-
gies, such as described for FimH and PapG, are instruments for identifying biomimetic 
antagonists as anti-adhesive therapeutics. α-d-mannosides inhibit attachment of UPEC via 
adhesins FimH and cranberry polyphenolic compounds via adhesins PagG. Further re-
search and development of these potential anti-adhesive compounds will most likely lead 
to a clinically applicable alternative to antibiotic treatment of UTI.
Abbreviations, acronyms, symbols. – C-HEGA – cyclohexylbutanoyl-N-hydroxyethyl-d-glucamide, 
CRD – carbohydrate-binding domain, ExPEC – extraintestinal pathogenic E. coli, GbO4 – globoside, 
MeMan – methyl-α-d-mannopyranoside, RIP – relative inhibitory potency , SfaI – S fimbrial adhesins 
I, TLR4 – toll-like receptor 4, UPEC – uropathogenic Escherichia coli, UTI – urinary tract infection
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